Theorem teams with Charles River on preclinical work

Theorem Clinical Research has struck a deal with Charles River Laboratories ($CRL), adding the early-phase-focused CRO's capabilities to its drug development platform.

Under the agreement, Charles River will provide bioanalysis, immunogenicity and immunology testing to support Theorem's clinical trials, offering clients an end-to-end platform for drug development, Theorem said.

Charles River's early-phase heft includes a wealth of animal models, state-of-the-art preclinical testing technology and a bioanalysis portfolio, making it a go-to partner for CROs in need of preclinical work, Executive Director Alan Bartlett said. Now, teaming up with Theorem, Charles River has found a new client base for its services.

"Sponsors will benefit from the experience of both organizations," Bartlett said in a statement. "The alliance will offer a seamless transition from preclinical testing into the clinical arena."

Like many early-stage CROs, Charles River is facing a decline in demand for discovery services, but the Wilmington, MA, researcher has managed to grow in a stilted market, last quarter seeing sales climb 2.9% to $292.9 million.

- read the announcement

Special Report: How can early-phase CROs stay afloat in a changing market?

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.